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ABSTRACT 
Tuberculosis poses a significant risk to global health with estimated 1.7 million deaths worldwide in 2016. One 
key issue in tuberculosis management relates to the drug pipeline, with drug development not keeping pace 
with the rate at which the disease expands and changes. Identifying and addressing factors that inhibit 
tuberculosis research and development is essential. Research to identify trends in the drug pipeline and evaluate 
the relations between these trends and other influencing factors will strengthen the existing body of knowledge, 
enabling improved decision-making on investment in drug research and development, and structuring incentives 
to encourage investment.  
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1. INTRODUCTION 
Tuberculosis (TB) is the ninth biggest cause of death worldwide, affecting the lives of over 10,4 million people 
in 2016 [1]. An estimated four million people (40% of TB cases) are undiagnosed each year; this figure increases 
to 77% among individuals with drug-resistant TB (DR-TB) [2]. In most developing countries, diagnosed patients 
face drawn-out delays (up to 28–30 days) in receiving feedback confirming their TB status, thus prolonging the 
time during which they are without appropriate treatment or until they undergo the necessary drug-susceptibility 
testing (DST) [1]. Diagnosing TB is the first step in treating affected people and preventing the transmission of 
the disease [2]. According to the World Health Organisation, infection rates will only decrease if, firstly, the 
country and local-level uptake of the diagnostic tools available increases significantly, and, secondly, investment 
in basic scientific research and the diagnostic pipeline is increased considerably [2]. 
 
DR-TB is a growing threat: in 2016, 600 000 new cases of resistance to rifampicin (the most effective first-line 
TB drug) were diagnosed, and 490 000 of these cases were diagnosed as multidrug-resistant TB (MDR-TB) [1]. 
The 2017 treatment outcome data show a global success rate of 83% for TB treatment and 54% for DR-TB [1]. 
DR-TB treatment has a noticeably lower success rate than that of TB. The need for further advancement in the 
development of more effective, safer, affordable, accessible, shorter course and better tolerated treatment 
regimens is evident, and is being investigated by stakeholders and researchers as this is of paramount importance 
to reduce the global prevalence of this disease [3].  
 
Despite research suggesting that the research and development (R&D) of TB drugs over the past few decades 
has not yielded any major breakthroughs, there has been noticeable progress in the TB treatment drug pipeline 
recently. Three drugs are currently in phase 34 of clinical development trials and are being distributed on a small 
scale to DR-TB patients [1]. Unfortunately, access to these drugs is restricted in developing countries, where 
the disease is most prevalent [3].  
 
Dowdy [23] describes TB as an “epidemic at a crossroads”. According to Dowdy, “strains of DR-TB will emerge 
that are more transmissible and more difficult to treat”, yet there are more drugs and technologies to use 
against the disease than ever before [23]. There is evidence that DR-TB can effectively be reversed, unlike most 
other DR pathogens. Thus, the next decade can either be one in which the TB epidemic becomes an 
“unprecedented global epidemic” or one in which the “global burden will be unprecedentedly reversed” [23]. 
According to Dowdy, the difference between these two outcomes lies with the global TB control community, 
and whether there is enough political will to prioritise the mitigation of the disease [23]. 
 
The end TB strategy is related to the Sustainable Development Goals and aims to “eliminate TB by 2030” [4]. In 
order to achieve the global goal of ending TB, it is estimated that an annual amount of $2 billion should be 
invested in TB R&D globally. Currently, approximately $650 million is spent on global TB R&D per year, which 
indicates that there is a significant investment gap for the development of TB drugs [4]. According to the 2016 
report on TB research funding, the lack of funding for TB is now a human rights issue in need of a political 
solution [2] & [4]. Lucica Ditiu, executive director of the Stop TB Partnership, states that the lack of funding for 
TB R&D is impacting everything related to the development of new drugs and technologies, with specific 
reference to: i) the rate at which new technologies become available to the market; ii) the state of the TB drug 
pipeline; iii) advocacy efforts; and iv) the possibility of reaching targets in global plans to end TB [4]. 
 
There is consensus in literature that investment in TB R&D is needed to increase the number of drugs that 
progress through the drug pipeline effectively [1] & [2]. Literature does not specify, however: i) why the private 
sector shows less interest in investing in TB compared to other diseases; ii) why TB drugs progress through the 
pipeline at a slower rate than drugs for other diseases; iii) the trends of drug R&D; and iv) what the major factors 
are that affect the drug movement of the TB drug pipeline. It is therefore argued in this paper that addressing 
the factors that affect the TB drug pipeline can contribute towards the advancement of effective progress of TB 
drugs through the R&D pipeline. 
 
This article aims to investigate the trends and factors affecting the advancement of drugs in the drug pipeline 
and the TB drug pipeline in particular, in order to: i) highlight the value of identifying factors causing a loss of 
efficiency in the pharmaceutical R&D process; ii) enable informed decision-making about advancing drug 
                                                     
4 Clinical development phases (1, 2 and 3) refer to the research studies, forming part of the drug R&D process, that determine 
whether a drug is safe and effective for human consumption. Each phase has different outcomes. The more advanced a drug 
is in the clinical trial phases, the higher the possibility for the drug to be accepted by regulatory agencies. 
486
 
SAIIE29 Proceedings, 24th – 26th of October 2018, Spier, Stellenbosch, South Africa © 2018 SAIIE 
 
 
 
3635-3 
 
 
 
development; and iii) facilitate discussions concerned with directing investment in drug R&D to contribute 
towards increasingly effective and efficient output of drugs from the TB drug pipeline. The relationships between 
pipeline trends and factors affecting the pharmaceutical and TB drug pipeline is discussed and analysed to 
determine similarities or differences between the pipelines. Potential areas for future research are identified. 
Lastly, the value of future research in this field for the existing body of knowledge is briefly investigated to 
establish whether an understanding of the pipelines might improve the effectiveness and efficiency of, 
specifically, the TB drug pipeline.   
2. METHOD 
In order to address the aim stated above, this study investigates two drug pipelines; firstly, the pharmaceutical 
drug pipeline (diseases non-specific) and secondly, the TB drug pipeline (disease specific). These two drug 
pipelines will be addressed separately and subsequently compared to establish similarities and differences. 
Figure 1 depicts the research inquiry process followed to investigate each pipeline in order to ultimately 
establish the value of identifying those factors and trends that affect the pharmaceutical pipeline.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As can be seen in Figure 1, the drug R&D process will be discussed first. Subsequently, both the pharmaceutical 
and TB drug pipelines will be discussed. Distinct systematic reviews of both pipelines (systematic review 1 and 
2) will be conducted, resulting in the identification of two sets of influencing factors and trends relating to drug 
pipelines. A separate analysis of each pipeline and a comparison of the two pipelines will follow to establish 
relationships within the pipelines and similarities and differences between the two pipelines. The analysis will 
result in understanding the impact of various factors on the pipelines, and possible ways to improve pipeline 
efficiency and effectiveness, based on pipeline trends. Finally, the value of the study regarding the improvement 
of the TB pipeline will be presented, followed by an evaluation of how this information might be used to improve 
the impact on the pharmaceutical or TB drug pipeline.  
Contextualisation 
Systematic literature review 1 
Influencing factors and trends 
Discussion 
PHARMACEUTICAL DRUG PIPELINE 
Drug R&D process 
Contextualisation 
Systematic literature review 2 
Influencing factors and trends 
Comparison 
Discussion 
TB DRUG PIPELINE 
Value of identifying those factors and trends affecting the pharmaceutical pipeline 
Figure 1: Research study method 
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3. DRUG RESEARCH AND DEVELOPMENT PROCESS 
Drug R&D refers to the process followed from product discovery to the successful development of a drug. It 
includes all research conducted and review processes completed up to the introduction of the new drug.  
 
The development of pharmaceutical drugs is an iterative, time consuming and costly process [5]. The process 
alternates between several factors, including: i) theoretical biology; ii) the appropriate use of animal assays to 
determine a compound’s biological activity in the body; and iii) optimising the chemical compounds with 
medicinal chemistry [5]. The cost of R&D for each successful new drug was estimated to be $2.6 billion in 2016, 
as opposed to $1 billion in 2000 [6]. Costs include the cost of failures, thus the cost of all the drugs screened, 
tested and assessed but not necessarily approved. PhRMA [5] states that the development costs of drugs are still 
rising and become even higher when the cost of research after drug approval is considered. Drug development 
is a lengthy process, lasting up to fifteen years from initial discovery to product launch. The duration of the drug 
development process can be influenced by various factors, including the testing and analysis of the drug for 
safety and efficacy. 
 
Drugs require approval from a recognised pharmaceutical regulatory agency, authorising the drug to be launched 
provided that it adheres to the international guidelines and standards set out for drugs [6]. One of the most 
well-known regulatory agencies is the Food and Drug Administration (FDA), the federal agency of the United 
States Department of Health and Human Services responsible for ensuring that organisations in the US, and a 
number of other countries, adhere to regulatory frameworks [7]. When a drug is FDA approved, it means the 
potential risk of the item is outweighed by its benefits, thus making it, legally, safe to use [7].  
 
To discover and develop a new drug, researchers must understand the basic causes of a disease in terms of 
proteins, genes and cells [8]. The information emerging from the disease-cause analysis is known as ‘targets’ 
and identifies the potential factors that can be affected by drugs to diagnose, prevent or treat a disease [8]. 
The validation of the identified targets, discovering the right molecule to interact with the target, and testing 
for safety and efficacy are only a few of the tasks to be completed [8]. The drug development process occurs in 
five distinct phases, namely: i) drug discovery; ii) the preclinical phase; iii) clinical trials; iv) the review phase; 
and v) post-marketing surveillance. Each stage contributes to fine-tuning the developing drug so that it is in the 
best possible state for the target disease. Figure 2 illustrates the phases in drug R&D, the stipulated number of 
compounds (drug candidates) per phase, as well as the average duration of each phase.  
 
 
Figure 2: Drug R&D process [8]  
 
The primary aims of the review process in drug R&D are to ensure that: i) drugs are safe for human consumption; 
ii) drugs are effective in treating the disease targeted; iii) drugs are affordable for users; and iv) the benefit of 
the new drug outweighs the potential risk [8]. The benefit versus risk ratio is determined by the FDA, or another 
regulatory agency, scrutinising the data collected in the preclinical and clinical findings. The drugs need to meet 
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the safety and efficacy standards set by regulatory bodies. Currently only 12% of candidate drugs (drugs in the 
R&D process) receive FDA approval [9].  
 
Although scientific advances enable a greater understanding of diseases at molecular level, it is evident that 
scientific, technical and regulatory challenges still exist in the R&D process [5]. According to PhRMA [5], an in-
depth analysis of the R&D process could clarify why the successful development of drugs takes so long.  
4. PHARMACEUTICAL DRUG PIPELINE  
This section focuses on the pharmaceutical sector. Firstly, it discusses the context of the pharmaceutical 
pipeline. Then a systematic literature review is conducted, and factors and trends that influence the pipeline 
are identified. Finally, any similarities or differences between the factors and trends are analysed and evaluated.    
4.1 Contextualisation: The pharmaceutical drug pipeline  
The drug pipeline refers to the set of drugs that a pharmaceutical company, or the entire pharmaceutical 
industry, in the process of discovering, research or development at a given point in time [10]. The drug pipeline 
encompasses the amount of active R&D taking place, thus serving as a form of reference to the extent of interest, 
investment and resource allocation in a specific drug or disease [11]. In the pharmaceutical industry, the drug 
pipeline includes all the processes from initial drug discovery to the introduction of the product for public 
consumption [10].  
 
The drug pipeline does not end when the drug development process has been completed and the drug approved 
for launch; ongoing research and data collection form part of post-approval studies [9]. These studies are 
conducted for as long as the product is used by patients and include the examination of the drug and its effects 
on drug users; these insights can also be used to expand treatment options in future drug development [9].  
 
The pharmaceutical pipeline is under tremendous pressure when the significant number of events, processes, 
stakeholders, circumstances and regulations influencing the outcome are considered. Great advances in science, 
technology and management practices in drug development have been made over the past 60 years; yet the 
number of new drugs approved per billion US dollars spent on drug development has decreased about 80-fold 
[12]. The time and cost challenges are well known for their impact on the drug industry. Another contributor to 
the loss of efficiency in the drug pipeline is the ‘curse of attrition’ [13]. This refers to the considerable number 
of drugs being rejected in clinical trial phases, as the drug progresses through the compulsory trials and processes 
[13]. The low success rate of compound development is further impaired by the amount of funds lost once a 
drug is rejected at such an advanced stage of development [13].  
 
The pharmaceutical industry strives to decrease the number of drug compounds exiting the R&D system without 
being approved, thereby minimising lost investment costs, research effort and time. An ideal scenario would 
entail a more extensive safety and efficacy test being initiated in earlier phases of the drug R&D process. The 
elimination of unsafe and ineffective compounds in an earlier phase would mean that less development effort 
goes to waste.  
4.2 Systematic literature review  
Numerous research studies have been aimed at pinpointing factors that contribute to the loss of efficiency in 
the pharmaceutical R&D process [27]. The value of identifying these factors lies within the opportunity to 
potentially address the identified factors in the R&D process, thus limiting the negative effect that it might have 
on the pharmaceutical pipeline. This study, however, aims to identify the factors that have a direct influence 
on the drug R&D process, thus affecting the state of the drug pipeline. A systematic literature review has been 
used to determine such factors. 
4.2.1 Systematic literature review method 
The literature review search was done in the Scopus5 literature database. The objective was to establish the 
factors that lead to a lack of efficiency in the pharmaceutical drug pipeline. Answering the following two 
research questions (RQs) will contribute to addressing the primary objective of the study effectively. 
                                                     
5 Scopus is the database of Elsevier, and the world’s largest abstract and citation database of peer-reviewed 
literature. Scopus provides global interdisciplinary and scientific information across all research fields. Scopus 
is free to use [27]. 
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• RQ 1: What factors influence the overall drug pipeline of the pharmaceutical industry? 
• RQ 2: What trends can be identified in the development of drugs over the past 10 years? 
 
Keywords for the search were derived from the two research questions and arranged in a logical manner. A 
search was completed with the search line: ("clinical trial" OR ((pharmaceutical OR drug*) W/5 (r&d OR pipeline 
OR development)) W/5 (factor* OR challeng* OR influenc* OR improv* OR affect*)). 
4.2.2 Systematic literature review results 
The search, using the keywords mentioned above, gave an output of 16 309 possibly relevant documents. The 
document set was further limited by type to journal sources only, excluding 1 017 articles. The document type 
was limited to articles, leading to 8 623 articles in total. The publication date was limited to a range from 2008 
to 2017, resulting in a total of 5 504 documents. Finally, all articles written in languages other than English were 
excluded, resulting in set of 5 099 documents. 
 
In order to reduce the number of documents in the document pool further, it was decided to use the top 200 
cited documents from the set of 5 099. To correct for the bias inherent in only selecting the top cited documents, 
all documents published from 2015 to 2017 were also included in the document pool. This resulted in a document 
pool of 200 (top cited) + 2 049 (published 2015-2017). Eleven documents were duplicates in the two sets, which 
gave a total of 2 238 preliminary, relevant documents. 
 
The titles of all 2 238 documents were scanned for relevancy to the two research questions. Consequently 147 
documents were deemed relevant. The abstracts of these 147 documents were reviewed and resulted in the 
final selection of 97 documents with information relevant to both RQ1 and RQ2. The abstracts of these 
documents were analysed from two perspectives. Firstly, the abstracts were comprehensively investigated to 
establish factors that correlate with RQ1 (see Section 4.3). Secondly, the abstracts were explored to identify 
trends that correspond with RQ2 (see Section 4.4).  
4.3 Results: Influencing factors 
The preliminary identification of influencing factors was conducted by investigating the abstracts of the 97 
documents and identifying factors that correlate with RQ1. In total, 39 factors were identified. The range of 
occurrence varied from a single occurrence to 13 occurrences across the 97 articles. Table 1 shows the most 
prominent factors present in the articles included in the dataset. 
Table 1: The top occurring influencing factors identified in the preliminary analysis of the document pool 
No. Influencing factor Occurrence 
1. Policy & regulatory issues 13 
2. 
Set-up of clinical trials; randomisation in trials (RCT); trial methodology & choice of 
metrics 
13 
3. 
Recruitment and retention of participants; enrolment & minority representation; 
little clinical trial awareness of potential participants 
11 
4. 
Complexity of trials; deal with multiple endpoints; better operational framework; 
clinical trial activation difficulty 
10 
5. Clinical trial risk 7 
6. Lack of transparency; accountability; accessibility of clinical trial information 7 
7. 
Quality of clinical trial; improve use of innovative clinical trial tools; quality of pre-
clinical trials 
7 
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8. 
Physician participation; relationships between stakeholders; collaboration; data 
sharing & intellectual property 
6 
9. Lack of capacity and funding; lack of ROI 5 
10. Ethical obstacles and issues 5 
 
The top four factors found to influence the pharmaceutical pipeline occurred in 10% or more of the document 
pool selected for this systematic review. All four factors are briefly discussed below. 
1. Policy and regulatory challenges refer to any challenge encountered in ensuring, establishing or 
completing the regulations laid out by the regulatory drug agencies of the pharmaceutical industry. 
These challenges might exist because of national or international policies and are often influenced or 
enforced by government. 
2. Clinical trial set-up refers to the way in which the clinical trials are organised, planned or arranged. 
The set-up determines how the activities of the trial phases will operate and what each step will entail. 
3. Participants of clinical trials refers to the patients on whom tests are being conducted. Participants 
usually volunteer for clinical trials and might be provided with some sort of incentive to participate. 
4. The complexity of clinical trials refers to the difficulty of completing and performing the actions 
required for the trials. It refers to the operational challenges experienced in carrying out the necessary 
protocols in all aspects of the clinical trials. 
4.4 Results: Pharmaceutical pipeline trends 
Trends in the pharmaceutical pipeline indicate a general direction in the development of or changes to the 
pipeline. Of the 97 abstracts reviewed, eight mentioned trends in the pharmaceutical drug pipeline. Four trends 
in drug R&D and pipelines are identified and investigated in this section, namely: i) R&D productivity; 
ii) investment capital and returns in the pharmaceutical sector; iii) clinical trial registration; and iv) the cost of 
clinical trials.  
4.4.1 R&D productivity 
The productivity of pharmaceutical R&D can be measured by various methods. According to Lendrem [14], 
productivity is measured by evaluating the number of new therapeutic drugs (NTDs) per billion dollars R&D spent 
per annum; Schulze et al. [15] evaluated the number of peak sales value of NTDs instead. The method of 
measurement used by Landrem [14] includes the effect of inflation-adjusted R&D costs.  
 
The productivity evaluation, as mentioned by Landrem [14], concluded that escalating R&D costs is a dominant 
feature influencing the productivity of R&D during the period 1990 to 2013. The rise in operating costs, according 
to Hammer and Champy [16], might be a result of a change in focus during the 1990s to maximise the 
development speed of drug R&D. The cycle times of successful molecules were halved from 1990 to 2001, but 
this led to an immense increase in development costs, ultimately affecting the entire drug development process. 
The productivity of R&D remained relatively constant over the period 1990 to 2013, but decreased drastically 
when inflation was considered. The increase in the inflation-adjusted R&D costs offered an explanation for the 
market decline in overall R&D productivity [14]. 
4.4.2 Investment capital and returns in the pharmaceutical sector 
The investment capital in this sector has decreased over time in response to many factors. These factors include 
preclinical scientific breakthroughs [17], clinical trial data, regulatory oversight, healthcare policies, pricing, 
technology and other economic changes related to drug discovery and development [18]. According to Thakor 
et al. [18], the most direct driver of capital flow in and out of the industry is the performance of pharmaceutical 
investments, thus providing attractive returns on the investments made. Some sources state, however, that not 
all pharmaceutical companies are struggling to realise returns, and that healthcare venture capital outperformed 
all other venture sectors over the past decades [18]. The annual returns of the pharmaceutical sector for the 
period 1980 to 2015 exceeded that of the stock market by 3%. The pharmaceutical portfolio also outperformed 
the market portfolio, where $1 invested in pharmaceutical companies in 1980 would be worth $114, compared 
with $44 if invested in the market at the same time [18].  
 
Each investment holds a certain amount of risk and volatilities in returns [18]. The Sharpe ratio, a measure of 
an investment’s return per unit of total risk, for the pharmaceutical sector was higher than that of the average 
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market. The high Sharpe ratio indicates that the risk-adjusted returns of the pharmaceutical sector were better 
than the average market for the period 1980 to 2015. 
4.4.3 Clinical trial registration 
The registration of clinical trials is necessary to increase their ethical and scientific value [19]. More than half 
of clinical trials are never published and are reported selectively, resulting in a waste of resources and decision-
making based on biased evidence, such as exclusive groups of patients used to participate in trials [19]. According 
to Viergever and Li [19], the number of registered clinical trials increased substantially between 2004 and 2013, 
from 3 297 to 23 384. Table 2 indicates the number of clinical trials registered, based on regional income groups. 
 
Table 2: Clinical trial registrations based on income groups, adapted from [19] 
Region (country income groups) Number of trials registered in 2005-
2013 
Percentage of all clinical trials 
registered in 2005–2013 
High-income countries 143 137 82.5 
Upper middle-income countries 24 937 14.4 
Lower middle-income countries 8 229 4.7 
Low-income countries 1 433 0.8 
Not specified 6 319 3.6 
 
It is evident from the information presented in Table 2 that high-income countries have the highest number of 
registered trials, representing 82.5% of all the clinical trials registered globally. In comparison, low-income 
countries conduct only 0.8% of the total number of clinical trials registered.  
 
The registration of clinical trials has improved transparency in pharmaceutical research by increasing access to 
information across the globe [19]. Challenges still exist though  [1]. These include: i) the quality of data 
available; ii) the accessibility of all clinical trial data; and iii) data searchability, data aggregation and linking 
data [19].  
4.4.4 The cost of clinical trials 
The cost of each clinical trial completed is influenced by a range of factors. The factors identified in Section 
2.3, amongst other things, affect the cost of the trial. Sertkaya et al. [20] evaluated all direct cost components 
and constructed a list. Their study [20] established that the average cost of each of the various stages are as 
depicted in Table 3.  
Table 3: Average cost per clinical trial phase, adapted from [20] 
Phase number Average range of clinical trial cost 
Phase 1 $1.4 million to $6.6 million 
Phase 2 $7 million to $19.6 million 
Phase 3 $11.5 million to $52.9 million 
 
The top three cost drivers, as established by Sertkaya et al. [20], were clinical procedure costs (15-22%), 
administrative staff costs (11-29%), and site monitoring costs (9-14%). It is important to note that these findings 
are based on trials funded by pharmaceutical and biotechnological organisations and not governments, academic 
institutions or other organisations [20].  
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4.5 Discussion of results 
The factors and trends identified can be evaluated based on the effect that they have on one another, and on 
how certain factors influence the trends within the pipeline.  
 
The productivity of drug R&D is a result of several factors, including the cost of R&D (as mentioned in Section 
4.4.1). Policies and regulations (influencing factor 1) potentially reduce the amount of NTDs introduced into the 
market. This does imply, however, that the process of eliminating unsafe and ineffective compounds from the 
pipeline is meticulous, resulting in reduced risk for potential drug users. The complexity and difficulty of trials 
(factor 4) mean that more time is required to conduct accurate studies. The quality of the trials also plays a 
role in the time it takes to complete the necessary procedures and whether it is necessary to repeat the study 
because of inadequate, inaccurate or insufficient data. The recruitment and retention of participants (factor 8) 
in the drug development process has a direct effect on the length of a study. It might take longer than planned 
to recruit all the participants necessary for the study, or the participants might be unable to complete the study, 
making the study unacceptable to regulatory authorities.  
 
The amount of investment capital and the returns of the pharmaceutical industry relies on the amount of risk 
(factor 5) involved in the drug development process. For each disease this risk differs. Clinical trial registration 
requires organisations to be transparent (factor 7) about the procedures of the clinical trials and the trial 
outcome and information. Lastly, the cost of clinical trials is affected by almost all aspects of the drug 
development process. The longer the process, the higher the cost of drug development. The attrition of drug 
compounds during the R&D process also plays a major role in the cost – funds are lost when compounds pursued 
for many years fail to qualify as safe and effective drugs. 
 
The state of the pharmaceutical pipeline is undoubtedly dependent on all the factors mentioned in Table 1. The 
trends identified in Section 4.4 discusses the impact of those factors with one another and the status quo of the 
pipeline.  
5. PHARMACEUTICAL TB DRUG PIPELINE  
This section describes the pharmaceutical TB drug pipeline. Firstly, various views on the TB drug pipeline are 
discussed. The current state and number of drugs in the pipeline are evaluated. A systematic literature review 
was conducted to determine influencing factors and trends in the TB drug pipeline. The results of the literature 
review are analysed at the end of the section. 
5.1 Contextualisation: The pharmaceutical TB drug pipeline  
Inspecting the drug pipeline of a specific disease differs from viewing the overall pharmaceutical pipeline. An 
overview of the TB drug pipeline incorporates characteristics of the disease and how those characteristics affect 
the drug development process.  
 
5.1.1 Different views of the TB drug pipeline 
According to the 2017 Pipeline Report [2], the overall TB drug pipeline can be divided into four explicit pipelines. 
The four pipelines are the: i) diagnostics; ii) prevention; iii) treatment; and iv) diagnostics and treatment for 
children pipelines. Each of the pipelines has different aims and objectives in the way it addresses the TB 
epidemic. These various TB drug pipelines are discussed below. 
 
I. Diagnostics pipeline  
 
The TB diagnostics pipeline includes the development of all technologies, tools and tests to identify and 
specify TB and the type of TB of the person tested. TB diagnostic tests include patient diagnosis and drug-
susceptibility testing [2]. TB diagnostics also include treatment monitoring technologies, which are 
necessary to establish whether treatment regimens are effectively improving or worsening the patient’s 
condition. 
 
II. Prevention pipeline 
 
Mycobacterium tuberculosis (MTB) is the causative agent of TB. According to a study completed in 2015 
[21], 1.7 billion individuals are infected with MTB. However, it is only when the MTB infection progresses to 
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the active, transmissible state that a person is said to have TB. For most people, an MTB infection will not 
progress to the active state; for others, certain life events (aging, pregnancy) or immune-compromising 
conditions might lead to an active TB infection [2].  
 
The TB prevention pipeline primarily entails the R&D of vaccines or other innovation therapies. According 
to Behr et al. [22], the two primary goals of TB vaccine development is to, firstly, find a vaccine to boost 
the current vaccination available to prevent active TB in adults infected with MTB and, secondly, to find a 
novel vaccine to replace existing vaccination for infants. Behr et al. [22] consider it important to pursue 
the parallel development of vaccines not only to prevent active TB from developing, but also to develop a 
vaccine to prevent sustained infection by MTB.    
 
III. Treatment pipeline 
 
The bacterial species MTB is treated with a combination of antibiotics [2]. Several antibiotics are used as 
first-line medicines to treat the infection. The extensive overuse and misuse of antibiotics since their 
introduction in the 1950s have led to a rise in DR-TB infections [23]. The DR infections occur because of 
inadequate or interrupted treatment or can be transmitted from one person to another. 
 
IV. Diagnostics and treatment for children pipeline 
 
Childhood TB has unique challenges with regard to diagnosis, prevention and treatment, as the disease 
differs considerably from TB in adults [24]. The BCG vaccine is primarily used by to prevent TB in children 
but is not fully protective and is not recommended for HIV-infected children. According to the 2017 WHO 
report, only 38% of TB-infected children are diagnosed and reported to national authorities each year [1]The 
diagnosis of childhood TB is complicated by the disease having non-specific symptoms. In most cases, 
children present smear-negative results, even though they are infected with the disease [24].  
 
This research study focuses on the treatment pipeline: the current state of drugs in R&D intended to treat TB. 
This study does not distinguish between drugs aimed at treating adults or children, but rather views the pipeline 
from a systems perspective.   
  
5.1.2 The current TB pipeline 
There are a significant number of challenges in the management of TB on a global scale [3]. A considerable 
number of organisations, stakeholders, researchers and advocates are working on developing drugs to mitigate 
the effect that TB has on patients. Yet a more effective, shorter, safer and more easily tolerable treatment 
regimen is needed to manage the disease effectively [3]. The current TB drug pipeline, as reported in March 
2018, consists of 14 candidate drugs for drug-susceptible, drug-resistant and latent TB. The 14 drugs are all in 
clinical stages of development; two drugs are in early stage development, nine are novel and in clinical trial 
phases 1 and 2, three have been approved and are in clinical trial phase 3 [3]. In addition to these drugs, other 
immune-based and host-directed treatment arrays are also under development [3]. The drug development 
industry has made extraordinary progress with the approval of two novel anti-TB drugs, bedaquiline and 
delamanid, in 40 years [25]. Figure 3 depicts the recent drug development pipeline for medicines currently 
progressing through clinical trials.  
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Figure 3: New global TB drug development pipeline [3] 
5.2 Systematic literature review process 
The objective of this literature review was to establish what existing literature says about factors that lead to 
the lack of efficiency in the TB drug pipeline, in particular. The trends experienced in the TB drug pipeline were 
investigated to determine the state of the current pipeline. This systematic review was conducted to replicate 
the platform created with the previous systematic review, making a comparison between the two pipelines 
possible.  
5.2.1 Systematic literature review method 
As in the systematic literature review described in Section 4.2, the document search was completed in Scopus. 
The RQs presented in Section 4.2.1 were adjusted to form new RQs that would apply to the TB drug pipeline 
instead of the pharmaceutical drug pipeline. Addressing these two RQs will assist in comprehending the TB drug 
pipeline.   
 
• RQ 3: What factors influence the TB drug pipeline? 
• RQ 4: What trends can be identified in the development of TB drugs over the past 10 years? 
 
The search line was as follows: (Tuberculosis OR tb) AND ("clinical trial" OR ((pharmaceutical OR drug*) W/5 (r&d 
OR pipeline OR development)) W/5 (factor* OR challeng* OR influenc* OR improv* OR affect*)). 
5.2.2 Systematic literature review results 
The search resulted in a total of 230 documents. The sources were limited to journals and conference 
proceedings, leading to 219 documents in the pool. Conference proceedings were added to this systematic 
review, and not to the systematic review in Section 4, because the document pool for this search was much 
smaller, since including TB narrowed the search extensively. The document type was then limited to articles 
and conference papers, leading to 121 documents. The publication date, as in the previous search, was limited 
to the last ten years (excluding 2018), resulting in 80 documents. The document pool was finally restricted to 
only English-language publications, leading to a total of 77 documents. The titles of the documents were scanned 
to find articles that mention anything that relates to RQ3 & 4. A total of 33 documents were found to be 
applicable to the RQs. The abstracts of these 33 documents were screened from two perspectives; firstly, to 
determine the factors influencing the TB drug pipeline (RQ3) and, secondly, to identify trends in the TB drug 
pipeline (RQ4).  
5.3 Results: Influencing factors  
With the first review of the 33 article abstracts, a total of 24 factors influencing the TB drug pipeline, thus 
relevant to RQ3, were identified. Table 4 shows the eight most frequently occurring factors identified. 
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Table 4: Top 8 factors influencing the TB drug pipeline 
No. Influencing factor Occurrence 
A. Drug resistance 6 
B. Developing countries 5 
C. Resource-constrained (limited) setting 5 
D. 
Complex structure of MTB within host; different physiological states 
of bacterium 
4 
E. 
Access to drugs; implementation of current & new treatment; low 
exposure 
3 
F. Lack of finances 2 
G. Not enough DST technology 2 
H. Uncertain predictive value of preclinical animal models 2 
 
 
The top three factors are briefly discussed below: 
A. For TB, drug resistance refers to the characteristic of the disease that develops in many patients as a 
result of their not taking the medicine as scheduled, or by the DR-TB being transmitted from one person 
to another. The effect of drug resistance on the TB drug pipeline was mentioned in six of the 33 articles 
(18%) scanned in the systematic review. Patients infected with DR-TB are resilient to the first-line drugs 
used to treat the disease, as mentioned in Section 1.  
B. Developing countries refers to the setting in which the disease occurs most often. Treating diseases in 
developing countries present challenges that do not necessarily occur in developed countries, thus 
making it a valid characteristic to consider with regard to the state of the drug pipeline.  
C. Resource-constrained setting refers to the capability of the region in which TB occurs to perform the 
necessary actions and allocate the required funds to have a positive influence on the development of 
drugs. 
5.4 Results: TB drug pipeline trends 
With the second review of the 33 article abstracts, three major trends surfaced in two articles. Additional 
literature was included to describe the trends in the TB drug pipeline effectively. Each of the three trends are 
described in this section. 
5.4.1 Funding trends by research category 
TB is being addressed by organisations globally. Unfortunately, the funding available to combat TB does not 
seem to receive the attention needed to effectively mitigate the disease. The global plan to stop TB recommends 
an annual $2 billion investment to accomplish the goal of ending TB by 2030 [2]. At present, the effective 
investment in TB R&D is approximately $650 million per year. Figure 4 indicates the total TB R&D funding for 
the period 2005 to 2015. 
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Figure 4: Total TB R&D funding, 2005-2015, [4] 
 
Funding per research category per year gives an indication of the focus of investors in TB R&D over the past 10 
years. The drug development received the most funding, achieving a maximum of $268 million in 2013, but 
decreasing with over $30 million to a less desirable $232 million in 2015 [4]. Diagnostics reached its funding peak 
with $111 in 2014 million, but decreased to $81 million in 2015; operational research achieved a maximum of 
$88 million in 2011, decreasing to $61 million in 2015 [4]. These figures indicate the decreased market interest 
in TB. 
5.4.2 Number of drug approvals 
The FDA approval of drugs for treating TB has been notably slow over the past 40 years [3]. The exception, 
however, is the approval of the two novel drugs bedaquiline and delaminid. At the time of writing, a third drug, 
pretomanid, is undergoing phase 3 clinical trials along with the two drugs mentioned previously [3].   
5.4.3 TB disease burden 
Measuring the effectiveness of the drugs, innovations and technologies launched is challenging. One way in which 
the success of the strategies used to end TB can be measured is by assessing the overall disease burden. Globally 
the TB mortality rate (measured per 100 000 population) decreased by 37% between the years 2000 and 2016 
[1].  
5.5 Discussion of results 
The amount of funding invested in TB drug R&D and the overall drug pipeline depends greatly on the return on 
investments in TB drug R&D [4]. The number of drug approvals for TB is influenced by the complex structure of 
MTB within the host (influencing factor D). The different physiological states of the bacterium (factor D) also 
lead to a greater variety of scenarios in which the drug compounds in development should act. The number of 
drug approvals is also affected by the strict policies and regulations put in place to ensure that only safe and 
effective drugs are introduced into the market.  
 
The disease burden of TB is subject to most of the factors listed in Table 4. Drug resistance (factor A) causes 
the disease to be less treatable with the drugs on the market. Because the disease is most prevalent in developing 
countries (factor B) with a constrained amount of resources (factor C), it decreases the likelihood that the 
impact of the disease can be mitigated effectively. When the access to drugs of patients infected with TB is 
limited (factor E), the effective treatment of those patients becomes unviable. The disease burden cannot be 
lessened if there is no easy access to the right types of drug for patients. Improving the availability of DST 
technology (factor G) will improve the ability of clinics to determine whether someone is infected with DR-TB 
or not, thus providing the patient with the right type of medicine.  
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6. COMPARISON BETWEEN PHARMACEUTICAL AND TB DRUG PIPELINES   
It is apparent that there are similarities and differences between the pipeline of the pharmaceutical industry 
and the TB drug pipeline. It is important to note that the pharmaceutical pipeline serves as a reference to which 
the TB drug pipeline is compared. 
6.1  Evaluation of influencing factors  
The top eight factors in the pharmaceutical sector focus mainly on improving the efficiency and productivity of 
the drug pipeline by ensuring that the drugs progressing through the clinical trial phases are approved as fast as 
possible and identifying reasons if this does not happen. The factors that occurred the most in the TB drug 
pipeline indicate something about the nature of the disease, the complexity of the disease itself and the state 
of the setting in which most TB cases occur. The only factor found in both pipelines is the lack of funding (factors 
9 and F in tables 1 and 3, respectively).  
 
It is evident that the TB drug pipeline cannot be examined without taking the circumstances and characteristics 
of the disease into account. These circumstances and characteristics include: i) the number of cases reported 
per year; ii) the success rates of drug treatments; iii) the regions in which this disease is most prevalent; iv) the 
complexity of treatment; and v) the length of the treatment course.   
6.2  Evaluation of pipeline trends 
Although there is a lack of funding and investment in both pipelines, it is evident that the funding gap in the TB 
drug pipeline is much greater than the funding gap in the general pharmaceutical industry, indicating that the 
investment gap is most likely not as prominent for the R&D of other drugs. 
 
The productivity of the development of TB drugs differs significantly compared to productivity in the 
pharmaceutical pipeline. The number and rate of TB drug approvals are much lower and slower than those in 
the pharmaceutical drug pipeline. This indicates the difficulty in finding an effective cure for TB and DR-TB, as 
a result of disease complexity and drug resistance.  
 
The prevalence of TB in developing countries gives rise to smaller returns on investment compared with the R&D 
for other diseases. It is assumed that pharmaceutical organisations or private investors aim to maximise their 
returns on investment. Consequently, TB R&D investment is not seen as a first option and funds are rather 
invested elsewhere.  
7. THE VALUE OF THE IDENTIFICATION AND ANALYSIS OF TRENDS AND INFLUENCING FACTORS IN THE 
PHARMACEUTICAL AND TB DRUG PIPELINES 
The value of the factors and trends identified in this study, and ways in which the identification of influencing 
factors and trends in drug pipelines might contribute towards more effective investment and better decision-
making, are discussed in this section. 
7.1  The ability of trend analysis to enable decision-making in TB R&D investment 
The trend and influencing factor analysis of the general pharmaceutical industry identified characteristics of 
the industry and sector in terms of market attractiveness, productivity and costs that would not be possible 
otherwise. Comparing the TB and general pipelines identifies gaps in the TB drug pipeline that do not exist in 
the general sector. The identification of these gaps serves as a platform to improve the TB drug pipeline. The 
TB drug pipeline undoubtedly requires more funding and investment to mitigate the disease effectively. 
Questions arise on how additional funding options will be made available or how investors will be encouraged to 
invest in this disease – keeping in mind that TB mostly occurs in developing countries with limited resources and 
relatively low returns on investment, and with the infection evolving day by day into an even more drug-resistant 
strain.  
 
It should be noted that all drug pipelines are similar, but that variance is caused by the disease itself. The 
disease, its characteristics, most popular region of occurrence, challenges, complexity, and all other factors 
affect the drug pipeline. TB has exceptional characteristics, as it is currently the infectious disease that kills 
the most people in the world.  
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Identifying trends in the TB drug pipeline not only identifies the characteristics of the disease, but also provides 
a platform to present to stakeholders and potential investors, encouraging contributions and influencing future 
investment decisions.  
7.2  Encouraging investment in TB R&D with the use of incentives 
Decision-making on investment in TB drugs includes the consideration of incentives [25]. Burki [25] remarks that, 
even if funds were to be sufficient, other incentives should be available to keep the sector sustainable, as the 
high development costs will not lead to profitable returns. Parys suggests that push (grants) and pull (the 
transferable priority review voucher scheme run by the FDA and advancement prizes for achieving a specified 
goal) mechanisms are the best way to encourage private companies to invest in the disease [25].  
 
Médicins Sans Frontières (MSF) proposed a new model for TB R&D based on push and pull mechanisms, with 
pooled intellectual property as an addition. The model is primarily aimed at separating the selling price of drugs 
from the R&D process costs [25]. The proposed MSF model, is intended to reduce the duplication of R&D efforts 
by different stakeholders, ensures open collaborative research, reduces the risk of compounds being rejected, 
and accelerates drug combination development [25] & [26]. To MSF’s disappointment, the WHO rejected the 
proposal in December 2013, and it was thus not pursued any further. 
7.3 The benefit of an in-depth understanding of the TB drug pipeline  
Understanding the drug pipeline, and more specifically the TB drug pipeline, creates the opportunity to forecast 
and strategise decision-making more accurately. Forecasting in pharmaceutical pipelines enables stakeholders 
to make more informed predictions of the unpredictable market, and to allocate funds more efficiently to areas 
lacking the required growth. The complete understanding of the drug pipeline presents the opportunity to adjust 
the overall drug development strategy to align with the goals of effectively mitigating the disease.  
8. CONCLUSION AND FURTHER RESEARCH 
The drug pipeline is a complex and interconnected system. Thirty-nine factors influencing the pharmaceutical 
drug pipeline have been identified through a systematic literature review. The foremost factors are regulations 
and policy, the set-up of clinical trials, and circumstances regarding the participants of clinical trials. Trends 
identified in the pharmaceutical industry include the relative stagnation of productivity (in terms of NTDs 
launched) and a decline in capital investment in the sector. The transparency of clinical trials has increased, as 
more trials have been registered over the past decade. The cost of clinical trials has sky-rocketed – clinical 
procedures, administrative staff and site monitoring costs are responsible for between 37% and 65 % of total 
trial costs.  
 
The complete / total TB drug pipeline can be divided into four distinct sub-pipelines. This study focused on the 
treatment pipeline only. The R&D in TB drugs has only recently made progress, with the approval of two novel 
drugs for the first time in 40 years. Twenty-four factors influencing the TB drug pipeline have been identified. 
The foremost factors are the increasing drug resistance of the infection, and the fact that disease occurring 
primarily in developing countries with limited resources. The trends most visible in the TB drug pipeline include 
the seeming shortage of private investment in TB R&D, and a lack of productivity (when based on drug approvals).   
 
The conclusion is that the realisation of returns in the pharmaceutical industry depends on the type of drug 
being developed and on certain characteristics of the disease being targeted. In the case of TB, the 
characteristics include the high prevalence of the disease in developing countries, making it unattractive as a 
potential investment. Looking at investment trends, it can be deduced that investments in diseases occurring 
mostly in resource-constrained countries hold greater risks for stakeholders, compared to diseases in developed 
countries with more funds available.  
 
Future research opportunities exist within the pharmaceutical R&D pipeline to identify characteristics that 
improve the market attractiveness of certain diseases in comparison with others. Research should be done to 
determine the features of diseases and the similarity of those features in various diseases that currently 
experience a lack of capital investment. Current and alternative finance mechanism schemes should be 
investigated to potentially improve the interest of private investors in diseases with unattractive characteristics.  
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